Ligand Pharmaceuticals Incorporated (LGND) Guidance & Earnings Results
On 2026-08-06 Ligand Pharmaceuticals Incorporated raised guidance: "Low end of 2026 adjusted EPS guidance raised; revenue guidance…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
LGNDLigand Pharmaceuticals IncorporatedFollow LGND — free
—
Price chart with a free account
- Market cap
- 6.1B
- P/E TTM
- 32.3
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 6 Aug 26 | Raised | Low end of 2026 adjusted EPS guidance raised; revenue guidance unchanged · full year |
| 7 May 26 | Raised | Incremental royalty revenue ~$25M from XOMA · full year |
| 26 Feb 26 | Reaffirmed | Reiterating 2026 financial guidance of $245-$285 million in revenues and adjusted earnings per diluted share of $8.00-$9.00 · full year |
| 6 Nov 25 | Raised | FY2025 revenue $225M-$235M; adjusted EPS $7.40-$7.65 · full year |
| 7 Aug 25 | Raised | FY2025 revenue raised to $200-225M from $180-200M; adjusted EPS raised to $6.70-7.00 from $6.00-6.25 · full year |
Ligand Pharmaceuticals Incorporated — questions
- What guidance did Ligand Pharmaceuticals Incorporated give?
- On 2026-08-06: "Low end of 2026 adjusted EPS guidance raised; revenue guidance unchanged"
- When does Ligand Pharmaceuticals Incorporated report earnings?
- Ligand Pharmaceuticals Incorporated's next earnings report is expected on 2026-10-29.
Every figure on this page comes from Ligand Pharmaceuticals Incorporated's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.